Sector Gamma AS Raises Stock Holdings in Takeda Pharmaceutical Co Ltd (NYSE:TAK)

Sector Gamma AS grew its stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 2.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 816,299 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Takeda Pharmaceutical makes up 2.4% of Sector Gamma AS’s portfolio, making the stock its 16th biggest holding. Sector Gamma AS’s holdings in Takeda Pharmaceutical were worth $14,040,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Coastal Investment Advisors Inc. grew its position in shares of Takeda Pharmaceutical by 59.8% during the second quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock worth $32,000 after purchasing an additional 643 shares in the last quarter. Stephens Inc. AR grew its position in shares of Takeda Pharmaceutical by 6.7% during the third quarter. Stephens Inc. AR now owns 11,704 shares of the company’s stock worth $201,000 after purchasing an additional 732 shares in the last quarter. HighTower Advisors LLC grew its position in shares of Takeda Pharmaceutical by 3.2% during the second quarter. HighTower Advisors LLC now owns 29,939 shares of the company’s stock worth $534,000 after purchasing an additional 919 shares in the last quarter. SRS Capital Advisors Inc. grew its position in shares of Takeda Pharmaceutical by 83.3% during the third quarter. SRS Capital Advisors Inc. now owns 2,200 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Advisory Services Network LLC grew its position in shares of Takeda Pharmaceutical by 101.6% during the second quarter. Advisory Services Network LLC now owns 2,076 shares of the company’s stock worth $37,000 after purchasing an additional 1,046 shares in the last quarter. Hedge funds and other institutional investors own 4.67% of the company’s stock.

Several analysts recently issued reports on the company. Daiwa Capital Markets cut Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research report on Thursday, August 15th. Cowen began coverage on Takeda Pharmaceutical in a research note on Friday, November 1st. They set a “market perform” rating and a $19.50 price target for the company. Jefferies Financial Group began coverage on Takeda Pharmaceutical in a research note on Tuesday, September 24th. They set a “buy” rating for the company. ValuEngine lowered Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, Zacks Investment Research raised Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $19.25.

Takeda Pharmaceutical stock traded up $0.52 during midday trading on Friday, reaching $20.07. 1,560,995 shares of the stock traded hands, compared to its average volume of 2,430,236. The stock’s fifty day moving average is $17.68 and its 200-day moving average is $17.56. Takeda Pharmaceutical Co Ltd has a 12 month low of $15.50 and a 12 month high of $21.61. The stock has a market cap of $60.07 billion, a P/E ratio of 39.35 and a beta of 0.70. The company has a quick ratio of 0.94, a current ratio of 1.45 and a debt-to-equity ratio of 1.00.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.59 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 12.52% and a net margin of 3.66%. The company had revenue of $7.56 billion during the quarter. On average, equities analysts predict that Takeda Pharmaceutical Co Ltd will post 1.99 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Further Reading: What does EPS mean?

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.